Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Germany,Netherlands,United States,Spain,France,Belgium,Sweden,Israel,Canada,Italy - Phase: complete
nct
Update Il y a 5 ans
A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039
The purpose of this study is to allow patients to receive VELCADE™ (bortezomib) for Injection who experienced progressive disease(PD) while receiving high-dose dexamethasone from the M34101-039 study.
Country
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Netherlands
,
Spain
,
Sweden
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This study will compare the efficacy of PS-341 versus high dose dexamethasone.
Country
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Ireland
,
Israel
,
Italy
,
Netherlands
,
Spain
,
Sweden
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Country
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Repinotan in Patients With Acute Ischemic Stroke
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Spain
,
Sweden
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Dose Ranging Study of Celivarone With Amiodarone as Calibrator for the Prevention of Implantable Cardioverter Defibrillator (ICD) Interventions or Death
The Primary objective was to assess the efficacy of Celivarone for the prevention of Implantable Cardioverter Defibrillator (ICD) interventions or death. Secondary objectives were: - To assess the tolerability and safety of the different dose regimens of Celivarone in the selected population. - To document Celivarone plasma levels during the study.
Country
Argentina
,
Australia
,
Belgium
,
Canada
,
Chile
,
Czech Republic
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Japan
,
Mexico
,
Netherlands
,
Norway
,
Poland
,
Portugal
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Turkey
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
This is a Phase 3, multi-national, open-label, 2-arm randomized study in patients with surgically incurable metastatic melanoma who have received no prior chemotherapy, or biochemotherapy for the treatment of metastatic disease. The primary objective of this trial is to compare overall survival for patients with advanced melanoma who are randomized to receive CP-675,206 with that of patients who are randomized to receive either dacarbazine or temozolomide (investigator choice)
Country
Argentina
,
Australia
,
Austria
,
Belgium
,
Canada
,
France
,
Germany
,
Greece
,
Israel
,
Italy
,
Mexico
,
Netherlands
,
Poland
,
Russian Federation
,
Slovakia
,
South Africa
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1